Citations

Clear

9383 citation(s) found for "Thomas, PS".

NRG-GI004/SWOG-S1610: Colorectal cancer metastatic dMMR immuno-therapy (COMMIT) study—A randomized phase III study of atezolizumab (atezo) monotherapyversus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients with deficient DNA mismatch repa
Lima, Caio Max Sao Pedro Rocha , Puhalla, Shannon L. , Guthrie, Katherine A. , Blanke, Charles D. , Jacobs, Samuel A., Hong, Theodore S. , Höchster, Howard S. , Overman, Michael J. , Yothers, Greg , Sanoff, Hanna K. , Cohen, Deirdre J , Henry, N. Lynn , Ganz, Patricia A. , Kopetz, Scott , Lucas, Peter C. , Wolmark, Norman , George, Thomas J.

Mayo Clinic

Journal of Clinical Oncology | June 21, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS3632-TPS3632

10.1200/jco.2024.42.16_suppl.tps3632 Get It

TPS3632 Background: Approximately 45% of dMMR/MSI-H mCRC in the immunotherapy arm progressed at 12 mos (KEYNOTE 177). We hypothesize that dMMR/MSI-H mCRC patients (pts) may be more effectively treated with the combination of PD-1/PD-L1 (PD-1) pathway blockade and mFOLFOX6/bevacizumab (bev) rather than with anti-PD-L1 therapy (atezo) alone. Preclinical work demonstrated synergistic effects between anti-PD-1/anti-VEGF as well as between oxaliplatin/anti-PD-1 in murine CRC models, and phase II data showed activity of anti-PD-1/anti-VEGF in chemotherapy refractory colon cancer. Upon AtezoTRIBE subgroup analysis of the 8 pts with dMMR mCRC treated with FOLFOXIRI+bev+atezo, median PFS was not reached, with the first pt having progression ~16 mos. Additionally, in other solid tumor malignancies, anti-PD-1 plus anti-VEGFr (i.e., HCC and RCC) as well as anti-PD-1 plus chemotherapy (i.e., gastroesophageal and lung cancers) combinations are standard first-line treatments. Methods: This two-arm prospective phase III open-label trial randomizes (1:1) mCRC dMMR/MSI-H to atezo monotherapy v mFOLFOX6/bev+atezo combination. Key inclusion criteria have been simplified on recent amendments to better mirror clinical practice for pts receiving mFOLFOX6/bev+atezo: One cycle of FOLFOX or CAPOX, with or without bev (or biosimilar) prior to enrollment allowed, dMMR tumor determined by local CLIA-certified IHC assay (MLH1/MSH2/MSH6/PMS2) or MSI-H by local CLIA-certified PCR or NGS panel; pts with total bilirubin ≤4.0 x ULN; duration of therapy for up to two years for both arms; imaging frequency on post-treatment follow-up have been reduced; as has measurable disease per RECIST. Primary endpoint is PFS. Assuming the atezo monotherapy control arm has a 48% PFS at 24 mos as assessed by site investigator, we have 80% power to detect a hazard ratio of 0.6 (equivalent to 64.4% PFS at 24 mos) with alpha 0.025 one-sided. Stratification factors include BRAFV600E status, metastatic site, and prior adjuvant CRC therapy. Secondary endpoints include overall survival, objective response rate, safety profile, disease control rate, and duration of response. Archived tumor tissue and blood samples will be collected for correlative studies. Harmonization of translational analyses is planned between GI004 (COMMIT) and A021502 (ATOMIC). Sample size has been modified with the accrual goal of 120 pts randomized between the two immunotherapy arms needed for study completion. Enrollment actively continues. Current accrual (as of 02-02-2024): 96/120. NCT02997228. Support: U10CA180868, -180822, -180888, UG1CA189867, U24CA196067; Genentech, Inc. Clinical trial information: NCT02997228 .
Riluzole for Degenerative Cervical Myelopathy
Pedro, Karlo M. , Badhiwala, Jetan H. , Ahn, Henry, Shaffrey, Christopher I. , Mummaneni, Praveen V. , Jacobs, W. Bradley , Riew, K. Daniel , Hilibrand, Alan S. , Kim, Kee D. , Fourney, Daryl R. , Santaguida, Carlo , Massicotte, Eric M. , Fehlings, Michael G. , Alvi, Mohammed Ali , Farhadi, H. Francis , Nassr, Ahmad , Arnold, Paul M. , Riew, Kiehyun Daniel , Kelly, Michael P. , Brodke, Darrel Scott , Vaccaro, Alexander R. , Wilson, Jason, Harrop, James Shields , Huang, Peng

Mayo Clinic

JAMA Network Open | June 21, 2024 | Volume: 7 | Issue: 6 | Pages: e2415643

10.1001/jamanetworkopen.2024.15643 | PMID 38904964 Get It

Importance The modified Japanese Orthopaedic Association (mJOA) scale is the most common scale used to represent outcomes of degenerative cervical myelopathy (DCM); however, it lacks consideration for neck pain scores and neglects the multidimensional aspect of recovery after surgery. Objective To use a global statistical approach that incorporates assessments of multiple outcomes to reassess the efficacy of riluzole in patients undergoing spinal surgery for DCM. Design, Setting, and Participants This was a secondary analysis of prespecified secondary end points within the Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-PROTECT) trial, a multicenter, double-blind, phase 3 randomized clinical trial conducted from January 2012 to May 2017. Adult surgical patients with DCM with moderate to severe myelopathy (mJOA scale score of 8-14) were randomized to receive either riluzole or placebo. The present study was conducted from July to December 2023. Intervention Riluzole (50 mg twice daily) or placebo for a total of 6 weeks, including 2 weeks prior to surgery and 4 weeks following surgery. Main Outcomes and Measures The primary outcome measure was a difference in clinical improvement from baseline to 1-year follow-up, assessed using a global statistical test (GST). The 36-Item Short Form Health Survey Physical Component Score (SF-36 PCS), arm and neck pain numeric rating scale (NRS) scores, American Spinal Injury Association (ASIA) motor score, and Nurick grade were combined into a single summary statistic known as the global treatment effect (GTE). Results Overall, 290 patients (riluzole group, 141; placebo group, 149; mean [SD] age, 59 [10.1] years; 161 [56%] male) were included. Riluzole showed a significantly higher probability of global improvement compared with placebo at 1-year follow-up (GTE, 0.08; 95% CI, 0.00-0.16; P = .02). A similar favorable global response was seen at 35 days and 6 months (GTE for both, 0.07; 95% CI, −0.01 to 0.15; P = .04), although the results were not statistically significant. Riluzole-treated patients had at least a 54% likelihood of achieving better outcomes at 1 year compared with the placebo group. The ASIA motor score and neck and arm pain NRS combination at 1 year provided the best-fit parsimonious model for detecting a benefit of riluzole (GTE, 0.11; 95% CI, 0.02-0.16; P = .007). Conclusions and Relevance In this secondary analysis of the CSM-PROTECT trial using a global outcome technique, riluzole was associated with improved clinical outcomes in patients with DCM. The GST offered probability-based results capable of representing diverse outcome scales and should be considered in future studies assessing spine surgery outcomes.
Predictors of Durable Remission After Successful Surgery for Cushing Disease: Results From the Multicenter RAPID Registry
Tenhoeve, Sam , Evans, James, Collopy, Sarah , Delery, William , Pacione, Donato , Silverstein, Julie , Gardner, Paul A. , Rotman, Lauren E., Yuen, Kevin C.J. , Barkhoudarian, Garni , Fernandez‐Miranda, Juan C. , Benjamin, Carolina , Kshettry, Varun R. , Zada, Gabriel , Catalino, Michael P. , Little, Andrew S. , Karsy, Michael , Van Gompel, Jamie, Karsy, Michael , Findlay, Matthew C. , Alt, Jeremiah A. , Rennert, Robert C , Couldwell, William T. , Evans, James, Kim, Won Bae , Kim, Albert H. , Chicoine, Michael , Gompel, Jamie J. Van

Mayo Clinic

Neurosurgery | June 21, 2024 | Volume: 95 | Issue: 4 | Pages: 761-769

10.1227/neu.0000000000003042 | PMID 39293794 Get It

BACKGROUND AND OBJECTIVE: Cushing disease (CD) affects mortality and quality of life along with limited long-term remission, underscoring the need to better identify recurrence risk. The identification of surgical or imaging predictors for CD remission after transsphenoidal surgery has yielded some inconsistent results and has been limited by single-center, single-surgeon, or meta-analyses studies. We sought to evaluate the multicenter Registry of Adenomas of the Pituitary and Related Disorders (RAPID) database of academic US pituitary centers to assess whether robust nonhormonal recurrence predictors could be elucidated. METHODS: Patients with treated CD from 2011 to 2023 were included. The perioperative and long-term characteristics of CD patients with and without recurrence were assessed using univariable and multivariable analyses. RESULTS: Of 383 patients with CD from 26 surgeons achieving postoperative remission, 288 (75.2%) maintained remission at last follow-up while 95 (24.8%) showed recurrence (median time to recurrence 9.99 ± 1.34 years). Patients with recurrence required longer postoperative hospital stays (5 ± 3 vs 4 ± 2 days, P = .002), had larger average tumor volumes (1.76 ± 2.53 cm 3 vs 0.49 ± 1.17 cm 3 , P = .0001), and more often previously failed prior treatment (31.1% vs 14.9%, P = .001) mostly being prior surgery. Multivariable hazard prediction models for tumor recurrence found younger age (odds ratio [OR] = 0.95, P = .002) and Knosp grade of 0 (OR = 0.09, reference Knosp grade 4, P = .03) to be protective against recurrence. Comparison of Knosp grade 0 to 2 vs 3 to 4 showed that lower grades had reduced risk of recurrence (OR = 0.27, P = .04). Other factors such as length of stay, surgeon experience, prior tumor treatment, and Knosp grades 1, 2, or 3 failed to reach levels of statistical significance in multivariable analysis. CONCLUSION: This multicenter study centers suggests that the strongest predictors of recurrence include tumor size/invasion and age. This insight can help with patient counseling and prognostication. Long-term follow-up is necessary for patients, and early treatment of small tumors may improve outcomes.
A Clinical Diagnostic Test for Calcium Release Deficiency Syndrome
Ni, Mingke , Saenen, Johan , Hoeksema, Wiert F. , Antiperovitch, Pavel , Arnaud, Marine , Tian, Shanshan, Sun, Bo , Estillore, John Paul , Wang, Ruiwu , Khan, Habib , Roston, Thomas M. , Mazzanti, Andrea , Giudicessi, John, Siontis, Konstantinos C. , Alak, Aiman, Acosta, J. Gabriel , Menon, Syamkumar M. Divakara, Tan, Nigel S. , Vivekanantham, Hari , Pandya, Tanvi, Cunningham, Jennifer , Gula, Lorne J. , Wong, Jorge , Amit, Guy , Scheinman, Melvin M. , Ackerman, Michael J. , Priori, Silvia G. , Sacher, Frédéric , Nof, Eyal , Glikson, Michael , Wilde, Arthur A.M. , Jensen, Henrik Kjærulf , Chen, S.R. Wayne , Roberts, Jason D. , Jensen, Henrik Kjærulf , Mazzanti, Andrea , Priori, Silvia , Dadon, Ziv , Ormerod, Julian O.M. , Tadros, Rafik , Christiansen, Morten Krogh , Steinberg, Christian , Giudicessi, John R. , Werf, Christian van der , Nazer, Babak , Krahn, Andrew D. , Gollob, Michael H. , Healey, Jeff S. , Glikson, Michael , Watkins, Hugh , Postema, Pieter G. , Belhassen, Bernard

Mayo Clinic

JAMA | June 20, 2024 | Volume: 332 | Issue: 3 | Pages: 204

10.1001/jama.2024.8599 | PMID 38900490 Get It

Importance Sudden death and cardiac arrest frequently occur without explanation, even after a thorough clinical evaluation. Calcium release deficiency syndrome (CRDS), a life-threatening genetic arrhythmia syndrome, is undetectable with standard testing and leads to unexplained cardiac arrest. Objective To explore the cardiac repolarization response on an electrocardiogram after brief tachycardia and a pause as a clinical diagnostic test for CRDS. Design, Setting, and Participants An international, multicenter, case-control study including individual cases of CRDS, 3 patient control groups (individuals with suspected supraventricular tachycardia; survivors of unexplained cardiac arrest [UCA]; and individuals with genotype-positive catecholaminergic polymorphic ventricular tachycardia [CPVT]), and genetic mouse models (CRDS, wild type, and CPVT were used to define the cellular mechanism) conducted at 10 centers in 7 countries. Patient tracings were recorded between June 2005 and December 2023, and the analyses were performed from April 2023 to December 2023. Intervention Brief tachycardia and a subsequent pause (either spontaneous or mediated through cardiac pacing). Main Outcomes and Measures Change in QT interval and change in T-wave amplitude (defined as the difference between their absolute values on the postpause sinus beat and the last beat prior to tachycardia). Results Among 10 case patients with CRDS, 45 control patients with suspected supraventricular tachycardia, 10 control patients who experienced UCA, and 3 control patients with genotype-positive CPVT, the median change in T-wave amplitude on the postpause sinus beat (after brief ventricular tachycardia at ≥150 beats/min) was higher in patients with CRDS ( P < .001). The smallest change in T-wave amplitude was 0.250 mV for a CRDS case patient compared with the largest change in T-wave amplitude of 0.160 mV for a control patient, indicating 100% discrimination. Although the median change in QT interval was longer in CRDS cases ( P = .002), an overlap between the cases and controls was present. The genetic mouse models recapitulated the findings observed in humans and suggested the repolarization response was secondary to a pathologically large systolic release of calcium from the sarcoplasmic reticulum. Conclusions and Relevance There is a unique repolarization response on an electrocardiogram after provocation with brief tachycardia and a subsequent pause in CRDS cases and mouse models, which is absent from the controls. If these findings are confirmed in larger studies, this easy to perform maneuver may serve as an effective clinical diagnostic test for CRDS and become an important part of the evaluation of cardiac arrest.
Exercise intervention may play a potential therapeutic role in patients with glioblastoma multiforme (Review)
Sharif, Salaheddin, Harman, Nicholas, Hydock, David S., Olson, Thomas P. , Sharif, Salaheddin M.

Mayo Clinic

World Academy of Sciences Journal | June 20, 2024 | Volume: 6 | Issue: 5 | Pages: No page available

10.3892/wasj.2024.256 Get It

KRAS Promotes GLI2-Dependent Transcription during Pancreatic Carcinogenesis
Sigafoos, Ashley N. , Tolosa, Ezequiel J. , Carr, Ryan M. , Fernández‐Barrena, Maite G. , Almada, Luciana L. , Pease, David R. , Hogenson, Tara L. , Arul, Glancis L. Raja , Mousavi, Fatemeh , Sen, Sandhya , Vera, Renzo E., Marks, David L. , Flores, Luis F. , LaRue-Nolan, Kayla C. , Wu, Chen , Vrabel, Anne M., Sicotte, Hugues , Smyrk, Thomas C. , Zhang, Lizhi , Oberg, Ann L. , Elsawa, Sherine F. , Pin, Christopher L. , Mao, Junhao , Fernández-Zapico, Martín E. , Raja Arul, Glancis L, Bamlet, William R , Sicotte, Hugues , Schenk, Erin L. , Chaffee, Kari G. , Oberg, Ann L , Chevet, Eric , Graham, Rondell P , Hagen, Catherine E , McWilliams, Robert R , Fernandez-Zapico, Martin E , Elsawa, Sherine F , Raja Arul, Glancis Luzeena , Carr, Ryan M , Bamlet, William R. , Rabe, Kari G. , Zaphiropoulos, Peter G. , Chevet, Éric , Graham, Rondell P. , Hagen, Catherine E. , Magliano, Marina Pasca di , McWilliams, Robert R.

Mayo Clinic

Cancer Research Communications | June 19, 2024 | Volume: 4 | Issue: 7 | Pages: 1677-1689

10.1158/2767-9764.crc-23-0464 | PMID 38896052 Get It

Abstract Aberrant activation of GLI transcription factors has been implicated in the pathogenesis of different tumor types including pancreatic ductal adenocarcinoma. However, the mechanistic link with established drivers of this disease remains in part elusive. In this study, using a new genetically engineered mouse model overexpressing constitutively active mouse form of GLI2 and a combination of genome-wide assays, we provide evidence of a novel mechanism underlying the interplay between KRAS, a major driver of pancreatic ductal adenocarcinoma development, and GLI2 to control oncogenic gene expression. These mice, also expressing KrasG12D, show significantly reduced median survival rate and accelerated tumorigenesis compared with the KrasG12D only expressing mice. Analysis of the mechanism using RNA sequencing demonstrate higher levels of GLI2 targets, particularly tumor growth–promoting genes, including Ccnd1, N-Myc, and Bcl2, in KrasG12D mutant cells. Furthermore, chromatin immunoprecipitation sequencing studies showed that in these cells KrasG12D increases the levels of trimethylation of lysine 4 of the histone 3 (H3K4me3) at the promoter of GLI2 targets without affecting significantly the levels of other major active chromatin marks. Importantly, Gli2 knockdown reduces H3K4me3 enrichment and gene expression induced by mutant Kras. In summary, we demonstrate that Gli2 plays a significant role in pancreatic carcinogenesis by acting as a downstream effector of KrasG12D to control gene expression.
A Scoping Review of the Intracranial Complications of Pediatric Sinusitis
Cress, Victoria , Jain, Amiti , Viaud‐Murat, Estelle , Patel, Punam A., Wiedermann, Joshua P. , Cress, Victoria J , Green, Katerina , Patel, Punam V.

Mayo Clinic

Otolaryngology–Head and Neck Surgery | June 19, 2024 | Volume: 171 | Issue: 4 | Pages: 937-945

10.1002/ohn.862 | PMID 38895865 Get It

Abstract Objective Intracranial complications of pediatric sinusitis are uncommon but are often associated with significant morbidity, especially when appropriate care is delayed. The present study aimed to identify commonalities for the development and progression of these complications in the pediatric population. Data Sources CENTRAL, CINAHL, Citation searching, ClinicalTrials.gov , Embase, Google Scholar, MEDLINE, PsycINFO, PubMed, Scopus, Web of Science, and World Health Organization. Review Methods A comprehensive literature search was performed using Preferred Reporting Items for Systematic Reviews and Meta‐analyses scoping review guidelines. Studies describing intracranial infections secondary to sinusitis in the pediatric population (age <18 years) were included. Studies in which adult and pediatric data were not separated and studies in which the pediatric cohort was fewer than 10 cases were excluded. Ultimately, 33 studies describing 1149 unique patient cases were included for data collection and analysis. Results Our analysis revealed intracranial complications were more common in adolescent males. Most children presented with over 1 week of vague symptoms, such as headache and fever. The majority of complications were diagnosed radiographically with computed tomography. Subdural empyema and epidural abscess were the most common intracranial complications reported. On average, patients were admitted for over 2 weeks. Most children were treated with a combination of antibiotics and surgical intervention. Complications were rare, but when present, were often associated with significant morbidity. Conclusion This scoping review of the available literature has provided insight into commonalities among pediatric patients who develop intracranial complications of sinusitis, providing a foundation for further study to inform medical and surgical decision‐making in this population.
Mohs Micrographic Surgery for Invasive Melanoma Allows for Tissue Preservation Compared With Wide Local Excision: A Retrospective Cohort Study
Rames, Melissa M. , Campbell, Elliott H. , Asamoah, Eucabeth, Trischman, Thomas , Kumar, Anagha , Vidal, Nahid Y. , Demer, Addison M. , Kumar, Anagha Bangalore , Demer, Addison

Mayo Clinic

Dermatologic Surgery | June 18, 2024 | Volume: 50 | Issue: 11 | Pages: 997-999

10.1097/dss.0000000000004270 | PMID 38888235 Get It

BACKGROUND While increasing evidence supports the safety and effectiveness of immunohistochemistry-assisted Mohs micrographic surgery (MMS) for superficially invasive melanoma, there is a paucity of the literature investigating its effect on final defect size. OBJECTIVE To evaluate the tissue sparing effect of MMS for melanoma. MATERIALS AND METHODS Three hundred and twenty-eight patients with early-stage (T1a/T1b) cutaneous melanomas treated with MMS from January 2008 to December 2018 were evaluated. Measured defect sizes after Mohs tumor extirpation were compared with anticipated defect size that would result from standard-margin wide local excision (WLE). Average actual versus anticipated defect areas were compared using a paired t-test (95% confidence intervals). RESULTS The following groups demonstrated a significantly smaller defect area for MMS-treated tumors when compared with anticipated standard-margin WLE defect: All tumors combined (13.8 cm2 vs 10.4 cm2, p < .001), tumors requiring 1 stage (13.6 cm2 vs 10.1 cm2, p < .001), and tumors requiring 2 stages (13.2 cm2 vs 10.5 cm2, p = .004). The majority of patients (83.5%, n = 274) achieved clear margins with 1 stage. CONCLUSION Immunohistochemistry-assisted MMS for early-stage invasive melanoma is associated with smaller final defect size and overall tissue sparing effect compared with standard WLE margins.
GCT-23. LONG-TERM FOLLOW-UP AND SURVIVALS OF PATIENTS WITH LOCALIZED CENTRAL NERVOUS SYSTEM NON-GERMINOMATOUS GERM CELL TUMORS (NGGCT) ENROLLED ON ACNS1123: A CHILDREN’S ONCOLOGY GROUP (COG) STUDY
Dhall, Girish , Onar‐Thomas, Arzu , Shaw, Dennis , MacDonald, Shannon M. , Murphy, Erin S. , Khatua, Soumen , Wang, Yu , Bartels, Ute , Fangusaro, Jason

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.278 Get It

Abstract BACKGROUND ACNS1123 was a Phase 2 study to determine whether irradiation could be safely reduced without impacting survival in a subgroup of NGGCT patients. METHODS Patients with localized disease who achieved a complete (CR) or partial response (PR) to induction chemotherapy were eligible to receive reduced dose/volume of irradiation to 30.6Gy whole ventricular field with 54Gy tumor-bed boost. RESULTS 107 eligible NGGCT patients were accrued. The median age of patients at enrollment was 11 years (3.7-21.6). Eighty patients (75%) were male. Location was pineal in 58 (55%), suprasellar in 37 (35%), ventricles in 6 (6%), and bifocal in 6 patients (6%). Sixty-six (61.7%) patients achieved a CR/PR post-induction and were eligible and evaluable for the primary objective and received reduced dose and volume of irradiation. Eight patients progressed; 6 had a distant spinal relapse (outside the irradiation field) and 2 had a local plus distant relapse. As of December 31, 2023, the median follow-up time for eligible and evaluable patients was 5.6 years (0.9-7.9) from enrollment. Except for an unrelated death due to SARS-CoV-2 at 5.5 years from enrollment, there were no grade 3 or higher adverse events at the 60-month follow-up timepoint and no disease progressions beyond 2 years. The 5-year progression-free and overall survival for all eligible and evaluable patients are 87.9% (95% CI:79%-94.8%) and 92.4% (95% CI:82.8%- 96.8%), respectively. CONCLUSION Although the study was closed prematurely due to the concern of increased spinal relapse, the current data suggest that most patients with localized NGGCT and a CR/PR to chemotherapy will survive long-term, and, in fact, have similar survival (PFS and OS) to patients enrolled on ACNS0122 who received full dose craniospinal irradiation. The key to future biologic studies and clinical trials is identifying at diagnosis those patients at high risk for relapse.
NFS-21. DEMOGRAPHIC, CLINICAL AND IMAGING CHARACTERISTICS OF NEWLY DIAGNOSED OPTIC PATHWAY GLIOMAS ASSOCIATED WITH NF1: RESULTS FROM THE INTERNATIONAL MULTICENTER NF1-OPG NATURAL HISTORY STUDY
Fisher, Michael J. , Listernick, Robert , Liu, Grant, Ferner, Rosalie E. , Lasky-Zeid, Janice, Ullrich, Nicole J. , Stasheff, Steven F., Rosser, T.H.L., Borcher, March, Arden-Holmes, Simone, Flaherty, Maree , Hummel, Trent R. , Motley, Walker, Bielamowicz, Kevin , Phillips, Paul H. , Reginald, Arun, Peragallo, Jason H. , Sato, Aimee , Hogan, Nick, McCourt, Emily A. , Ranka, Milan P., Campen, Cynthia , Beres, Shannon , Stearns, Duncan , Örge, Faruk , O’Halloran, Henry S., Oattes, Julius, Reddy, Alyssa , Brodsky, Michael A., Donahue, Sean P., Blank, Peter M K de , Gutmann, David H. , Heidary, Gena , Bornhorst, Miriam , Rosser, Teena, Bouffet, Éric , Wolf, David S. , El-Dairi, Mays , Mater, David Van , Tarczy‐Hornoch, Kristina , Klesse, Laura J. , Foreman, Nicholas K. , Allen, Jeffrey C. , Moertel, Christopher L. , Areaux, Raymond G. , Crawford, John Ross , Brodsky, Michael, Esbenshade, Adam J. , Cutter, Gary , Avery, Robert A.

Mayo Clinic

Neuro-Oncology | June 18, 2024 | Volume: 26 | Issue: Supplement_4 | Pages: 0-0

10.1093/neuonc/noae064.579 Get It

Abstract BACKGROUND Treatment and clinical management decisions for children with NF1-OPGs remain challenging as most existing data are retrospective and have not included standardized visual outcomes. In this study, we prospectively enrolled newly diagnosed NF1-OPGs and performed standardized neuro-oncology and ophthalmology assessments in order to develop evidence-based guidelines for monitoring and treatment. METHODS Children with NF1-OPG on MRI who were evaluated by both a study ophthalmologist and neuro-oncologist/NF1 expert within 1 month of radiologic diagnosis were eligible for enrollment. All subjects attempted quantitative visual acuity using Teller acuity cards (TAC) as well as ATS-HOTV testing. The neuro-oncologist/NF1 expert provided reasons for obtaining the MRI as well as initiating treatment, if applicable. Descriptive statistics calculated the success rate of acquiring TAC and reasons to obtain the MRI. RESULTS Two-hundred fifty subjects from 22 institutions were enrolled and had at least one visit beyond baseline (Median age 3.1 years, range 0.1–16.8; 53% female). TAC was successfully acquired in both eyes (N=195, 78%) and at least one eye in (N=206, 82%). ATS-HOTV was successfully acquired in both eyes (N=97, 39%) and at least one eye in (N=98, 39%). The two most common reasons to obtain an MRI were screening due to a diagnosis of NF1 (N=99, 39%) and ophthalmologic concern (N=81, 32%). At enrollment, continued observation occurred in a majority of subjects (N=221, 88%) while treatment with chemotherapy was initiated in only 11% (N=29). Twenty-nine (11%) subjects initially observed transitioned to treatment after enrollment (range: 2.5–25 months) thus far. DISCUSSION We present a prospective multicenter study of children with newly diagnosed NF1-OPGs. The ability to acquire quantitative visual acuity was higher than anticipated. The frequency of NF1-OPGs requiring treatment is lower than previously reported. Regression models of clinical and MRI features that prompted immediate treatment with chemotherapy versus observation will be discussed.